A Phase 3 interventional study of Naltrexone and placebo in Alcohol Use Disorder (AUD), sponsored by Shenzhen Sciencare Medical Industries Co., Ltd.. Not yet recruiting. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-02-25.
Sponsored by Shenzhen Sciencare Medical Industries Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 95 studies testing naltrexone in Alcoholism — 5 open to participants now, 5 under way, 2 of them phase 3. Naltrexone · Alcoholism.
Among the 95 studies testing naltrexone in Alcoholism, this one is the 14th largest by planned enrollment, is one of 2 that started in 2026, is one of 21 in phase 3, and was the 95th registered.
1,676 studies on the registry are indexed under Alcoholism; 331 are open to participants now.
Browse Alcoholism studies →5 of the 95 studies testing naltrexone in Alcoholism are open now, in 1 country. Recruiting first, the newest first:
Yale University · Sites in United States
Ages 18–80
Milky Kohno · Sites in United States
Ages 18–60 · Healthy volunteers
Johns Hopkins University · Sites in United States
Ages 21–65
Albert Einstein Healthcare Network · Sites in United States
Ages 18+
By country, each count listing its studies:
Naltrexone: first FDA approval 1984 (REVIA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 237 Alcoholism studies recruiting now, 84 (35%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 26 · Phase 3 22 · Phase 4 39
First in 1992; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 240 is above the median of 88 across 1,430 interventional studies indexed under Alcoholism.
Median enrollment 108 across the 95 interventional studies. Of the 86 that completed or were terminated, 45 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 95 have an industry lead sponsor. The 10 most frequent:
Shenzhen Sciencare Medical Industries Co., Ltd. is the lead sponsor of 4 studies on the registry; 2 are open to participants now.
Shenzhen Sciencare Medical Industries Co., Ltd. has 1 study filed under Alcoholism — fewer than ten, so there is no comparison to draw.
1 of the studies testing naltrexone in Alcoholism that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07433413Phase 3Shenzhen Sciencare Medical Industries Co., Ltd.Evaluate the Efficacy and Safety of Naltrexone Hydrochloride Implant in Patients With Alcohol Use Disorder | 2027-04-01 |
Add it to your calendar (.ics) → With an account.
Among the 95 studies testing naltrexone in Alcoholism, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial.
The study plans to enroll 240 adult patients with Alcohol Use Disorder (AUD). After providing written informed consent and undergoing screening for eligibility criteria, eligible subjects will be randomized in a 2:1 ratio to receive treatment in either the experimental group (1.5 g Naltrexone Hydrochloride Implant plus non-specific supportive psychotherapy) or the control group (placebo implant plus non-specific supportive psychotherapy).
On Day 1, subjects will receive a single subcutaneous implantation via a small abdominal incision, receiving either the Naltrexone Hydrochloride Implant or the placebo implant. Following implantation, subjects will be hospitalized for at least 2 hours (the investigator may extend this observation period up to 3 days based on the patient's condition). Subjects will change the wound dressing by themselves on postoperative Day 3.
Efficacy and safety assessments will continue through Week 24 post-randomization/dosing, involving a total of 11 visits. Among these, Visit 5 (Week 3) will be conducted via telephone, while all other visits will be performed as outpatient clinic visits.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of moderate to severe Alcohol Use Disorder (AUD) based on the , Fifth Edition (DSM-5) criteria (meeting four or more diagnostic criteria; refer to Appendix 1 for details).
Exclusion Criteria:
Pregnant, breastfeeding, or pregnant with a positive pregnancy test at screening. This includes women of planning to become pregnant during the study.
Note: Women of childbearing potential are defined as those who are biologically capable of becoming pregnant. To be considered not of childbearing potential, a female subject must meet one of the following: 1) Have had a hysterectomy or bilateral oophorectomy; or 2) Be , defined as having no menses for more than 12 consecutive months.
Significant abnormality in liver function (e.g., or ALT > 3 times the ), liver failure (e.g., presence of ascites, jaundice, coagulopathy, hepatorenal syndrome, or hepatic encephalopathy), or liver/gallbladder ultrasound findings that may significantly impact the assessment of the drug's efficacy and safety.
History of severe pancreatitis or severe delirium tremens. Presence of any severe/uncontrolled systemic diseases (e.g., respiratory, cardiovascular, gastrointestinal, neurological, hematological, urogenital, or endocrine disorders) or psychiatric disorders (e.g., Major Depressive Disorder, Schizophrenia, Bipolar Disorder) or other major illnesses, which in the Investigator's judgment could interfere with the provision of , make study participation unsafe, complicate the interpretation of study outcome data, or otherwise affect the achievement of study objectives.
Potential need for hospitalization or surgery during the study period, including scheduled elective surgeries that cannot be postponed.
Diagnosis of a Substance Use Disorder (other than alcohol or tobacco) based on criteria within the past year (prior to randomization/dosing), such as benzodiazepines, amphetamines, opioids, or cocaine.
Use of anti-relapse medication (e.g., Naltrexone) or receipt of systemic psychological support therapy within 30 days prior to randomization/dosing.
Currently receiving treatment for substance use disorders (e.g., opioids, amphetamines, alcohol), or received opioids within 7 days prior to randomization/dosing, or may require opioid treatment during the study; or positive urine drug screen for opioids, cannabis, amphetamines, etc., or positive naloxone challenge test on the day of randomization/dosing.
Suicidal risk based on Investigator's clinical judgment, or history of suicidal or self-mutilating behavior.
Allergy to the investigational product or its (polylactic acid, magnesium stearate) or local anesthetics.
Currently participating in any investigational drug or device study, or has used any investigational drug or device within 30 days prior to randomization/dosing.
Skin infection at the implantation site, systemic skin disease, or keloid scarring that may affect the assessment of the investigational drug's efficacy and safety.
Clinical or laboratory evidence of (HIV) or Syphilis infection.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects in the experimental group will receive the 1.5 g Naltrexone Hydrochloride Implant plus non-specific supportive psychotherapy.
Drug: Naltrexone
Placebo Implant plus non-specific supportive psychotherapy
Drug: placebo
Dosage Form: Implant Specification: 150 mg/Tablet Dosage and Administration: Subcutaneous implantation of 10 tablets (1500 mg) Duration of Treatment: Single administration
Dosage Form: Implant Specification: 150 mg/Tablet Dosage and Administration: Subcutaneous implantation of 10 tablets (1500 mg) Duration of Treatment: Single administration
Proportion of Heavy Drinking Days During the 24-Week Observation Period Post-Randomization/Post-Dosing
Specifically, this is calculated as the number of heavy drinking days divided by the number of days at risk for heavy drinking, with the aforementioned days counted up to the date of discontinuation of efficacy observation. "Days at risk for heavy drinking" are defined as the number of days a subject is under efficacy observation starting from the date of hospital discharge following implant administration. Drinking rates are assessed based on the Timeline Follow-Back (TLFB) method, utilizing the daily drinking record form (Appendix 11) completed by the subject and their family members. Heavy drinking is defined as consumption of ≥5 standard drinks per day for males and ≥4 standard drinks per day for females.
Time frame: 24-Week
Reduction of ≥2 levels in WHO alcohol risk grading
Specifically, this refers to the change from the baseline WHO alcohol risk level to the level assessed during weeks 21-24. The baseline WHO alcohol risk level is calculated based on TLFB alcohol consumption data collected during the 2-week period prior to detoxification. The WHO alcohol risk level assessed at weeks 21-24 post-randomization/post-dosing is calculated based on the daily drinking record form completed by the subject and their family members.
Time frame: 24-week
Alcohol Consumption (Total Amount Consumed Over 24 Weeks)
Calculated based on the daily drinking record form (completed by the subject and their family members) using the Timeline Follow-Back (TLFB) method.
Time frame: 24-week
Percentage of Days Abstinent (PDA)
Specifically, this is calculated as the number of days with no alcohol consumption divided by the number of days at risk. The aforementioned days are counted up to the date of discontinuation of efficacy observation. "Days at risk" are defined as the number of days a subject is under efficacy observation, starting from the date of hospital discharge following implant administration. This metric is calculated based on the drinking record form using the Timeline Follow-Back (TLFB) method. Alcohol consumption is defined as any recorded drinking behavior, regardless of the amount or frequency consumed.
Time frame: 24-week
Longest Continuous Abstinence Duration
Specifically, this refers to the longest consecutive number of days without alcohol consumption from the time of randomization/dosing until loss to follow-up or study completion. This metric is calculated based on the daily drinking record form (completed by the subject and their family members) using the Timeline Follow-Back (TLFB) method.
Time frame: 24-week
Proportion of Participants Without Heavy Drinking During the Study Observation Period
Specifically, this refers to the proportion of subjects who did not engage in heavy drinking from randomization/dosing until loss to follow-up or study completion. This metric is calculated based on the daily drinking record form (completed by the subject and their family members) using the Timeline Follow-Back (TLFB) method.
Time frame: 24-week
Alcohol Craving Score
Craving scores are assessed at 1, 2, 4, 8, 12, 16, 20, and 24 weeks post-randomization/post-dosing using a Visual Analog Scale (VAS). VAS Assessment: The VAS consists of a horizontal line. The left end is marked as "0," indicating "No craving," and the right end is marked as "10," indicating "Extreme craving." The intermediate sections represent varying degrees of craving. Subjects are asked to self-evaluate and select a numerical value between 0 and 10 that best represents their current level of craving. A higher numerical value indicates a higher degree of craving.
Time frame: 24-week
Personal and Social Functioning
Assessment of personal and social functioning at 4, 8, 12, 16, 20, and 24 weeks post-randomization/post-dosing using the Personal and Social Performance scale (PSP). PSP Total Score Rating Guidelines 71-100: These ratings reflect mild difficulties. 31-70: These ratings reflect various degrees of functional impairment. 0-30: These ratings reflect functional disability, indicating that the patient requires active support or close supervision
Time frame: 24-week
Pleasure Scale Score (Snaith-Hamilton Pleasure Scale, SHAPS)
Assessment of the level of agreement regarding pleasure responses in various enjoyable situations at 4, 8, 12, 16, 20, and 24 weeks post-randomization/post-dosing. This is evaluated using the Snaith-Hamilton Pleasure Scale (SHAPS).
Time frame: 24-week
Family APGAR Questionnaire
A qualitative assessment of family members' satisfaction regarding five basic family functions at 4, 8, 12, 16, 20, and 24 weeks post-randomization/post-dosing. This assessment is conducted using the Family APGAR Questionnaire.
Time frame: 24-week
Breath Alcohol Concentration (BrAC)
Measurement of breath alcohol concentration at 1, 2, 4, 8, 12, 16, 20, and 24 weeks post-randomization/post-dosing using a digital breath alcohol tester.
Time frame: 24-week
Proportion of Participants Requiring Hospitalization for Detoxification
Specifically, this refers to the proportion of subjects who required hospitalization for alcohol detoxification following randomization/dosing.
Time frame: 24-week
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Mar 2026; primary completion for Apr 2027, 12 months later.
Of 25 phase 3 interventional studies under Alcoholism, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 54. This study's planned 12 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Naltrexone
Shenzhen Sciencare Medical Industries Co., Ltd.